ArticleFrontiers in immunology2025
Mechanistic study of the hsa_circ_0074158 binding EIF4A3 impairing sepsis-induced endothelial barrier.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota and sepsis: mechanisms, clinical correlations, and therapeutic prospects.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis remains a major clinical challenge, characterized by high rates of morbidity, mortality, and healthcare burden. Its complex pathogenesis involves multiple factors, with damage to the vascular endothelial barrier being a key component. Currently, there are no widely accepted biomarkers that demonstrate high sensitivity and specificity for sepsis, and treatment mainly focuses on supportive care without specific therapeutic targets. Recent research suggests that circRNA has potential as both a biomarker and a therapeutic target. In previous studies, the harmful role of hsa_circ_0074158 in worsening sepsis-induced endothelial barrier dysfunction was demonstrated through both Methods: This study examined how hsa_circ_0074158 affects endothelial barrier function in sepsis. The role of hsa_circ_0074158 (circ_Ctnna1 in mice) in sepsis-related endothelial barrier dysfunction was studied using both Results: In both LPS-treated human umbilical vein endothelial cells (HUVECs) and cecal ligation and puncture (CLP) murine models, the overexpression of hsa_circ_0074158 (the mouse homolog of hsa_circ_0074158 is named circ_Ctnna1) significantly decreased CTNNA1 mRNA stability and increased endothelial hyperpermeability, while its knockdown restored barrier integrity. Mechanistically, RNA pull-down and RNA RIP assays demonstrated that hsa_circ_0074158 directly binds to the RNA-binding protein (RBP) EIF4A3, which decreases the stability of CTNNA1 (mRNA) and the production of α-catenin, subsequently impairing endothelial barrier function in sepsis. Rescue experiments showed that dual targeting of hsa_circ_0074158 and EIF4A3 restored endothelial barrier function. The dysregulation of the hsa_circ_0074158/EIF4A3 axis exacerbates sepsis-induced endothelial barrier dysfunction by destabilizing CTNNA1 mRNA, posing a critical medical challenge due to its complex pathophysiology. Conclusions: This study provides new insights into the molecular mechanisms of sepsis and suggests potential therapeutic targets for its treatment. Further research is needed to explore the clinical application of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.